Spravato® vs. IV Ketamine: Understanding Your Options

A comparison of Spravato® (esketamine) nasal spray and IV ketamine: FDA status, how each is given, duration, monitoring, insurance, and when each may be the right choice.

11 min read
Reviewed February 2025
Tasel Health Clinical Team

Clinically Reviewed: Board-Certified Psychiatrist |Next Review: February 2026

Ketamine
Spravato
Treatment Comparison
Depression

Key Takeaways

  • Spravato® is FDA-approved for TRD and for depressive symptoms with acute suicidal ideation; IV ketamine for depression is off-label.
  • Spravato® = nasal spray in-clinic + ~2 hr observation; IV ketamine = infusion (40–60 min) + monitoring.
  • Both require a ride home and no driving until the next day after sleep.
  • Insurance often covers Spravato® when criteria are met; IV ketamine coverage varies.
  • Your team will help choose based on indication, insurance, and your medical history.

Comparison at a Glance

FactorSpravato® (Esketamine)IV Ketamine
FDA status (depression)Approved (TRD; acute suicidal ideation)Off-label
RouteNasal sprayIV infusion
Typical sessionSpray + ~2 hr observation40–60 min infusion + monitoring
SettingIn-clinic, REMS programIn-clinic
InsuranceOften covered when criteria metVaries
DrivingNo driving until next day after sleep; ride requiredSame

When Each May Be Chosen

Spravato® is often chosen when you want an FDA-approved option that may be covered by insurance for TRD or acute suicidal ideation, and when your clinic participates in the REMS program. IV ketamine may be chosen when you need a different protocol, when Spravato® isn't available or covered, or when your doctor recommends it based on your history. Both require medical screening and same-day transportation; your provider will help you decide.

Frequently Asked Questions

Which is FDA-approved for depression?

Spravato® (esketamine) nasal spray is FDA-approved for treatment-resistant depression in adults (with an oral antidepressant) and for depressive symptoms in MDD with acute suicidal ideation/behavior. IV ketamine for depression is off-label.

How is each one given?

Spravato® is a nasal spray you use in-clinic under staff guidance, then you're observed for about 2 hours. IV ketamine is given through a vein as an infusion, typically 40–60 minutes, with monitoring during and after.

Does insurance cover them?

Spravato® is often covered by insurance when criteria are met (e.g., TRD or acute suicidal ideation). IV ketamine for depression is usually off-label and coverage varies; some plans cover it, others don't.

When might my doctor choose one over the other?

Choice depends on FDA approval needs, insurance, clinic availability, and your medical history. Spravato® may be preferred when insurance covers it and REMS can be met; IV ketamine may be chosen for protocol flexibility or when Spravato® isn't an option.

Are driving restrictions the same?

Yes. For both, you cannot drive or operate machinery until the next day after a full night's sleep. A ride home is required after every session.

How long does a typical session take?

Spravato®: administration plus about 2 hours of observation. IV ketamine: infusion (often 40–60 min) plus monitoring time. Total clinic time varies by site.

Related Articles

In a Mental Health Crisis?

If you're in immediate danger or thinking about hurting yourself, please get help right away:

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before making decisions about your treatment. If you're experiencing a mental health emergency, call 911 or text/call 988 (Suicide & Crisis Lifeline) immediately.

Still Have Questions?

Our experienced medical team is here to help you understand Deep TMS™ treatment and determine if it's right for you. Contact us for a personalized consultation.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with our medical team for personalized treatment recommendations.